N-(3-carbamoyl-1-methyl-1H-pyrazol-4-yl)-6-(piperazin-1-yl)picolinamide

ID: ALA4537124

PubChem CID: 117871724

Max Phase: Preclinical

Molecular Formula: C15H19N7O2

Molecular Weight: 329.36

Molecule Type: Unknown

Names and Identifiers

Canonical SMILES:  Cn1cc(NC(=O)c2cccc(N3CCNCC3)n2)c(C(N)=O)n1

Standard InChI:  InChI=1S/C15H19N7O2/c1-21-9-11(13(20-21)14(16)23)19-15(24)10-3-2-4-12(18-10)22-7-5-17-6-8-22/h2-4,9,17H,5-8H2,1H3,(H2,16,23)(H,19,24)

Standard InChI Key:  FTCJIDMJVYLNAE-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 24 26  0  0  0  0  0  0  0  0999 V2000
   24.4016  -15.9522    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.6921  -16.3601    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.6916  -17.1765    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.3997  -17.5861    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   25.1099  -17.1733    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   25.1070  -16.3582    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   25.8189  -17.5795    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   25.8216  -18.3967    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   26.5253  -17.1686    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   25.1153  -18.8076    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.3628  -18.4804    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.8180  -19.0895    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   24.2290  -19.7959    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   25.0277  -19.6232    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   25.6353  -20.1697    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   25.4659  -20.9691    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   26.4124  -19.9167    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   23.0050  -19.0067    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.4022  -15.1369    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   25.1118  -14.7297    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   25.1139  -13.9160    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.4081  -13.5034    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   23.6985  -13.9106    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.6947  -14.7304    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  1  1  0
  5  7  1  0
  7  8  1  0
  7  9  2  0
  8 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  1  0
 13 14  2  0
 14 10  1  0
 14 15  1  0
 15 16  2  0
 15 17  1  0
 12 18  1  0
 19 20  1  0
 19 24  1  0
 20 21  1  0
 21 22  1  0
 22 23  1  0
 23 24  1  0
  1 19  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA4537124

   US9586948, Example 10

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 329.36

Molecular Weight (Monoisotopic): 329.1600

AlogP: -0.42

#Rotatable Bonds: 4

Polar Surface Area: 118.17

Molecular Species: BASE

HBA: 7

HBD: 3

#RO5 Violations: ┄

HBA (Lipinski): 9

HBD (Lipinski): 4

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 13.03

CX Basic pKa: 8.77

CX LogP: 0.71

CX LogD: -0.67

Aromatic Rings: 2

Heavy Atoms: 24

QED Weighted: 0.70

Np Likeness Score: -2.15

References

1. Hanisak J, Seganish WM, McElroy WT, Tang H, Zhang R, Tsui HC, Fischmann T, Tulshian D, Tata J, Sondey C, Devito K, Fossetta J, Garlisi CG, Lundell D, Niu X..  (2016)  Efforts towards the optimization of a bi-aryl class of potent IRAK4 inhibitors.,  26  (17): [PMID:27476420] [10.1016/j.bmcl.2016.07.048]

Source

Source(1):

• Scientific Literature